{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:58:20Z","timestamp":1784735900995,"version":"3.55.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Study Objectives<\/jats:title>\n                  <jats:p>Post hoc analyses from the phase 3 REST-ON trial evaluated efficacy of extended-release once-nightly sodium oxybate (ON-SXB; FT218) vs placebo for daytime sleepiness and disrupted nighttime sleep in narcolepsy type 1 (NT1) and 2 (NT2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were stratified by narcolepsy type and randomized 1:1 to ON-SXB (4.5 g, week 1; 6 g, weeks 2\u20133; 7.5 g, weeks 4\u20138; and 9 g, weeks 9\u201313) or placebo. Assessments included mean sleep latency on Maintenance of Wakefulness Test (MWT) and Clinical Global Impression-Improvement (CGI-I) rating (coprimary endpoints) and sleep stage shifts, nocturnal arousals, and patient-reported sleep quality, refreshing nature of sleep, and Epworth Sleepiness Scale (ESS) score (secondary endpoints) separately in NT1 and NT2 subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The modified intent-to-treat population comprised 190 participants (NT1, n = 145; NT2, n = 45). Significant improvements were demonstrated with ON-SXB vs placebo in sleep latency for NT1 (all doses, p &amp;lt; .001) and NT2 (6 and 9 g, p &amp;lt; .05) subgroups. Greater proportions of participants in both subgroups had CGI-I ratings of much\/very much improved with ON-SXB vs placebo. Sleep stage shifts and sleep quality significantly improved in both subgroups (all doses vs placebo, p &amp;lt; .001). Significant improvements with all ON-SXB doses vs placebo in refreshing nature of sleep (p &amp;lt; .001), nocturnal arousals (p &amp;lt; .05), and ESS scores (p \u2264 .001) were reported for NT1 with directional improvements for NT2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinically meaningful improvements of a single ON-SXB bedtime dose were shown for daytime sleepiness and DNS in NT1 and NT2, with less power for the limited NT2 subgroup.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sleep\/zsad152","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T13:26:15Z","timestamp":1685366775000},"source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-6506","authenticated-orcid":false,"given":"Yves","family":"Dauvilliers","sequence":"first","affiliation":[{"name":"Department of Neurology, Sleep-Wake Disorders Center, Gui-de-Chauliac Hospital, Institute for Neurosciences of Montpellier INM, INSERM, University of Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roth","sequence":"additional","affiliation":[{"name":"Sleep Disorders and Research Center, Henry Ford Health System , Detroit, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-2974","authenticated-orcid":false,"given":"Richard","family":"Bogan","sequence":"additional","affiliation":[{"name":"University of South Carolina School of Medicine, Columbia, SC, USA"},{"name":"Medical University of SC , Charleston, SC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Thorpy","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4494-0195","authenticated-orcid":false,"given":"Anne Marie","family":"Morse","sequence":"additional","affiliation":[{"name":"Geisinger Commonwealth School of Medicine, Geisinger Medical Center, Janet Weis Children\u2019s Hospital , Danville, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Roy","sequence":"additional","affiliation":[{"name":"Ohio Sleep Medicine Institute , Dublin, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Dubow","sequence":"additional","affiliation":[{"name":"Avadel Pharmaceuticals , Chesterfield, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-5020","authenticated-orcid":false,"given":"Jennifer","family":"Gudeman","sequence":"additional","affiliation":[{"name":"Avadel Pharmaceuticals , Chesterfield, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"issue":"9","key":"2023111005201965700_CIT0001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"5","key":"2023111005201965700_CIT0002","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.sleep.2014.02.001","article-title":"The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings","volume":"15","author":"Black","year":"2014","journal-title":"Sleep Med."},{"issue":"5","key":"2023111005201965700_CIT0003","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-Third Edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest."},{"key":"2023111005201965700_CIT0004","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","edition":"3"},{"issue":"27","key":"2023111005201965700_CIT0005","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med."},{"key":"2023111005201965700_CIT0006","doi-asserted-by":"crossref","first-page":"101306","DOI":"10.1016\/j.smrv.2020.101306","article-title":"Diagnosis of central disorders of hypersomnolence: a reappraisal by European experts","volume":"52","author":"Lammers","year":"2020","journal-title":"Sleep Med Rev."},{"issue":"2","key":"2023111005201965700_CIT0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci."},{"issue":"3","key":"2023111005201965700_CIT0008","doi-asserted-by":"crossref","first-page":"e13203","DOI":"10.1111\/jsr.13203","article-title":"Narcolepsy type 2: a rare, yet existing entity","volume":"30","author":"Baumann-Vogel","year":"2021","journal-title":"J Sleep Res."},{"issue":"6","key":"2023111005201965700_CIT0009","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.5665\/sleep.3756","article-title":"Challenges in diagnosing narcolepsy without cataplexy: a consensus statement","volume":"37","author":"Baumann","year":"2014","journal-title":"Sleep."},{"issue":"2","key":"2023111005201965700_CIT0010","doi-asserted-by":"crossref","first-page":"zsab285","DOI":"10.1093\/sleep\/zsab285","article-title":"Narcolepsy with intermediate cerebrospinal level of hypocretin-1","volume":"45","author":"Postiglione","year":"2022","journal-title":"Sleep."},{"issue":"5","key":"2023111005201965700_CIT0011","doi-asserted-by":"crossref","first-page":"zsac052","DOI":"10.1093\/sleep\/zsac052","article-title":"Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1","volume":"45","author":"van der Hoeven","year":"2022","journal-title":"Sleep."},{"issue":"1","key":"2023111005201965700_CIT0012","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"2023111005201965700_CIT0013","doi-asserted-by":"crossref","first-page":"101709","DOI":"10.1016\/j.smrv.2022.101709","article-title":"Clinical considerations for the diagnosis of idiopathic hypersomnia","volume":"66","author":"Dauvilliers","year":"2022","journal-title":"Sleep Med Rev."},{"issue":"1","key":"2023111005201965700_CIT0014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5664\/jcsm.6882","article-title":"The MSLT is repeatable in narcolepsy type 1 but not narcolepsy type 2: a retrospective patient study","volume":"14","author":"Ruoff","year":"2018","journal-title":"J Clin Sleep Med."},{"issue":"12","key":"2023111005201965700_CIT0015","doi-asserted-by":"crossref","first-page":"zsx164","DOI":"10.1093\/sleep\/zsx164","article-title":"Test-retest reliability of the multiple sleep latency test in central disorders of hypersomnolence","volume":"40","author":"Lopez","year":"2017","journal-title":"Sleep."},{"issue":"5","key":"2023111005201965700_CIT0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000525282","article-title":"Heterogeneity in estimates of incidence and prevalence of narcolepsy: a systematic review and meta-regression analysis","volume":"56","author":"Wang","year":"2022","journal-title":"Neuroepidemiology."},{"issue":"1","key":"2023111005201965700_CIT0017","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13311-021-01051-4","article-title":"A practical guide to the pharmacological and behavioral therapy of narcolepsy","volume":"18","author":"Franceschini","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"9","key":"2023111005201965700_CIT0018","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/ene.14888","article-title":"European guideline and expert statements on the management of narcolepsy in adults and children","volume":"28","author":"Bassetti","year":"2021","journal-title":"Eur J Neurol."},{"issue":"9","key":"2023111005201965700_CIT0019","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.5664\/jcsm.9328","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline","volume":"17","author":"Maski","year":"2021","journal-title":"J Clin Sleep Med."},{"key":"2023111005201965700_CIT0020","volume-title":"Full prescribing information","author":"XYREM (sodium oxybate oral solution, CIII)","year":"2022"},{"key":"2023111005201965700_CIT0021","volume-title":"Full prescribing information","author":"XYWAV (calcium, magnesium, potassium, and sodium oxybates oral solution, CIII)","year":"2022"},{"key":"2023111005201965700_CIT0022","volume-title":"Summary of product characteristics","author":"XYREM (sodium oxybate)","year":"2020"},{"issue":"5","key":"2023111005201965700_CIT0023","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","article-title":"Treatment options for narcolepsy","volume":"30","author":"Barateau","year":"2016","journal-title":"CNS Drugs"},{"issue":"9","key":"2023111005201965700_CIT0024","doi-asserted-by":"crossref","first-page":"955","DOI":"10.5664\/jcsm.3004","article-title":"Disrupted nighttime sleep in narcolepsy","volume":"9","author":"Roth","year":"2013","journal-title":"J Clin Sleep Med."},{"key":"2023111005201965700_CIT0025","volume-title":"The voice of the patient: narcolepsy","author":"Center for Drug Evaluation and Research (CDER)","year":"2014"},{"issue":"1","key":"2023111005201965700_CIT0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5664\/jcsm.9638","article-title":"Disrupted nighttime sleep and sleep instability in narcolepsy","volume":"18","author":"Maski","year":"2022","journal-title":"J Clin Sleep Med."},{"issue":"6","key":"2023111005201965700_CIT0027","doi-asserted-by":"crossref","first-page":"zsac054","DOI":"10.1093\/sleep\/zsac054","article-title":"Linking clinical complaints and objective measures of disrupted nighttime sleep in narcolepsy type 1","volume":"45","author":"Barateau","year":"2022","journal-title":"Sleep."},{"key":"2023111005201965700_CIT0028","volume-title":"Full prescribing information","author":"LUMRYZ\u2122 (sodium oxybate for extended-release oral suspension, CIII)","year":"2023"},{"issue":"6","key":"2023111005201965700_CIT0029","doi-asserted-by":"crossref","first-page":"zsab200","DOI":"10.1093\/sleep\/zsab200","article-title":"Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy","volume":"45","author":"Kushida","year":"2022","journal-title":"Sleep."},{"issue":"4","key":"2023111005201965700_CIT0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40263-022-00904-6","article-title":"Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial","volume":"36","author":"Roth","year":"2022","journal-title":"CNS Drugs"},{"key":"2023111005201965700_CIT0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.sleep.2016.07.010","article-title":"Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy","volume":"24","author":"Black","year":"2016","journal-title":"Sleep Med."},{"issue":"9","key":"2023111005201965700_CIT0032","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.5664\/jcsm.9326","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment","volume":"17","author":"Maski","year":"2021","journal-title":"J Clin Sleep Med."},{"issue":"7","key":"2023111005201965700_CIT0033","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","article-title":"Sodium oxybate improves excessive daytime sleepiness in narcolepsy","volume":"29","author":"Black","year":"2006","journal-title":"Sleep."},{"issue":"5","key":"2023111005201965700_CIT0034","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5664\/jcsm.6576","article-title":"AASM scoring manual updates for 2017 (version 2.4)","volume":"13","author":"Berry","year":"2017","journal-title":"J Clin Sleep Med."},{"issue":"6","key":"2023111005201965700_CIT0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep."},{"key":"2023111005201965700_CIT0036","author":"American Academy of Sleep Medicine"},{"key":"2023111005201965700_CIT0037","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.sleep.2021.03.014","article-title":"2018 worldwide survey of health-care providers caring for patients with narcolepsy: WSS narcolepsy task force","volume":"82","author":"Rosenthal","year":"2021","journal-title":"Sleep Med."},{"key":"2023111005201965700_CIT0038","volume-title":"Cataplexy","author":"Mirabile","year":"2020"},{"issue":"8","key":"2023111005201965700_CIT0039","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5664\/jcsm.2922","article-title":"Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia","volume":"9","author":"Trotti","year":"2013","journal-title":"J Clin Sleep Med."},{"issue":"6","key":"2023111005201965700_CIT0040","doi-asserted-by":"crossref","first-page":"zsaa009","DOI":"10.1093\/sleep\/zsaa009","article-title":"Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences","volume":"43","author":"Dauvilliers","year":"2020","journal-title":"Sleep."},{"issue":"7","key":"2023111005201965700_CIT0041","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm."},{"issue":"6","key":"2023111005201965700_CIT0042","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am J Manag Care."},{"key":"2023111005201965700_CIT0043","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2016.04.082","article-title":"Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis","volume":"216","author":"Weeda","year":"2016","journal-title":"Int J Cardiol."},{"key":"2023111005201965700_CIT0044","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.sleep.2022.09.011","article-title":"Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: phase 1 study in healthy volunteers","volume":"100","author":"Bogan","year":"2022","journal-title":"Sleep Med."},{"issue":"4","key":"2023111005201965700_CIT0045","doi-asserted-by":"crossref","first-page":"672.e1","DOI":"10.1016\/j.clinthera.2021.01.017","article-title":"Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults","volume":"43","author":"Seiden","year":"2021","journal-title":"Clin Ther."}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsad152\/50632303\/zsad152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/46\/11\/zsad152\/52997554\/zsad152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/46\/11\/zsad152\/52997554\/zsad152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T05:21:15Z","timestamp":1699593675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsad152\/7185271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,29]]},"published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsad152","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,5,29]]},"article-number":"zsad152"}}